Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: $AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AGILE THERAPEUTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AGILE THERAPEUTICS's position in the market.
Rhea-AI Summary
Agile Therapeutics, Inc. (Nasdaq: AGRX) reports a 21% increase in net revenue to $6.7 million in Q3 2023, with a gross margin growth to 63%. The company reaffirms its expected full-year 2023 net revenue of at least $25 million and anticipates positive cash flow from operations in Q1 2024. Management will host a conference call on November 9, 2023, at 8:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
-
Rhea-AI Summary
Agile Therapeutics, Inc. will report its third quarter 2023 financial results on November 9, 2023. A live conference call and webcast will be held at 8:30 a.m. ET to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
-
Rhea-AI Summary
Agile Therapeutics grants inducement award to new CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
Rhea-AI Summary
Maxim Group upgrades Agile Therapeutics Inc. (NASDAQ:AGRX) to a 'buy' rating with a one-year price target of $5, nearly 180% increase from current level. Twirla sales accelerating significantly in 2Q23, expected to continue. Nurx partnership expands retail channel presence. 2023 revenue estimate increased to $25.3M, 2024 estimate to $42.9M. Gross margins expected to expand to 70% in 4Q23. Financing overhang but breakeven could come by 1H24. Upgrade to Buy, establishing a 12-month price target of $5.00.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
-
Rhea-AI Summary
Agile Therapeutics to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
-
Rhea-AI Summary
Agile Therapeutics (NASDAQ:AGRX) reported significant growth in revenue from its birth control patch, Twirla, in its second-quarter financial results. Net revenue from Twirla reached $5.5 million, a 44% increase from the previous quarter and a 159% increase from Q2 2022. Demand for the patch rose 158% year over year, contributing to the triple-digit revenue growth. Twirla factory sales were also up 42% from the previous quarter and 188% year over year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
Rhea-AI Summary
Agile Therapeutics, Inc. (Nasdaq: AGRX) reported second quarter 2023 net revenue of $5.5 million, a 44% increase from the first quarter 2023. Twirla demand and factory sales also saw significant growth. Gross margin grew to 58% in the second quarter 2023. The company reaffirmed its expected full year 2023 net revenue in the range of $25-$30 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.2%
Tags
-
Rhea-AI Summary
Agile Therapeutics, Inc. will report second quarter 2023 financial results on August 9, 2023. A live conference call and webcast will be held at 8:30 a.m. ET to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
Rhea-AI Summary
Agile Therapeutics partners with FPA Women's Health and vitaCare Prescription Services to expand access to Twirla, its low-dose weekly birth control patch. The partnerships aim to make Twirla more widely available through telehealth platforms and regional clinics. Agile Therapeutics expects to reach its $25-$30 million target net revenue for the year. Access to birth control has significant benefits for women and society, including reducing teen pregnancies and maternal deaths, increasing educational opportunities, and reducing poverty.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
AGILE THERAPEUTICS INC
Nasdaq:AGRX
AGRX Rankings
AGRX Stock Data
2.64M
6.85M
0.42%
3.71%
7.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
Princeton
About AGRX
agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.